Know Cancer

or
forgot password

Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma


N/A
19 Years
N/A
Open (Enrolling)
Both
Lymphoma, Large B-Cell, Diffuse

Thank you

Trial Information

Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma


Inclusion Criteria:



- CD20+ diffuse large B cell lymphoma confirmed

- Therapy naïve for lymphoma

- 19 years or older

- Written informed consent

Exclusion Criteria:

- Cannot understand informed consent

- Age under 19 years old

- Previous chemotherapy or radiation therapy for lymphoma

- Known pregnancy or urine/serum hCG (+)

- Unable to lie down still on back for about 30 minutes

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Change from baseline in summed peak standardized uptake value lean (SULpeak) after 3 cycles

Outcome Description:

Change in summed SULpeak between baseline FDG PET/CT before chemotherapy and mid-therapy interim FDG PET/CT after 3 cycles in DLBCL patients

Outcome Time Frame:

baseline and 3 cycles after starting chemotherapy, approximately 49 to 57 days after beginning R-CHOP

Safety Issue:

No

Principal Investigator

Seok-Goo Cho, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Catholic University of Korea

Authority:

Korea: Food and Drug Administration

Study ID:

KC11EISI0293

NCT ID:

NCT01357733

Start Date:

March 2012

Completion Date:

March 2016

Related Keywords:

  • Lymphoma, Large B-Cell, Diffuse
  • Diffuse, Large B-Cell, Lymphoma
  • 18F Fluorodeoxyglucose
  • Radionuclide-Emission Computed Tomography
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Name

Location